
SPECIAL SERIES: QUALITY CARE SYMPOSIUM
Original Contributions
Article Tools

OPTIONS & TOOLS
COMPANION ARTICLES
ARTICLE CITATION
DOI: 10.1200/OP.22.00128 JCO Oncology Practice - published online before print November 17, 2022
PMID: 36395436
Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer










2VA Palo Alto Health Care System, Palo Alto, CA
Abstract
Patients with metastatic cancer benefit from advance care planning (ACP) conversations. We aimed to improve ACP using a computer model to select high-risk patients, with shorter predicted survival, for conversations with providers and lay care coaches. Outcomes included ACP documentation frequency and end-of-life quality measures.
In this study of a quality improvement initiative, providers in four medical oncology clinics received Serious Illness Care Program training. Two clinics (thoracic/genitourinary) participated in an intervention, and two (cutaneous/sarcoma) served as controls. ACP conversations were documented in a centralized form in the electronic medical record. In the intervention, providers and care coaches received weekly e-mails highlighting upcoming clinic patients with < 2 year computer-predicted survival and no prior prognosis documentation. Care coaches contacted these patients for an ACP conversation (excluding prognosis). Providers were asked to discuss and document prognosis.
In the four clinics, 4,968 clinic visits by 1,251 patients met inclusion criteria (metastatic cancer with no prognosis previously documented). In their first visit, 28% of patients were high-risk (< 2 year predicted survival). Preintervention, 3% of both intervention and control clinic patients had ACP documentation during a visit. By intervention end (February 2021), 35% of intervention clinic patients had ACP documentation compared with 3% of control clinic patients. Providers' prognosis documentation rate also increased in intervention clinics after the intervention (2%-27% in intervention clinics, P < .0001; 0%-1% in control clinics). End-of-life care intensity was similar in intervention versus control clinics, but patients with ≥ 1 provider ACP edit met fewer high-intensity care measures (P = .04).
Presented as an oral presentation at the 2021 ASCO Quality Care Symposium in Boston MA, on September 24, 2021.
Conception and design: Michael F. Gensheimer, Manali I. Patel, Winifred Teuteberg, Briththa Seevaratnam, Jennifer Hansen, Jan DeNofrio, Divya Parikh, Heather Wakelee, Kavitha Ramchandran
Financial support: Briththa Seevaratnam, Kavitha Ramchandran
Administrative support: Rachel Hildebrand, Briththa Seevaratnam, Jennifer Hansen, Kaidi Moore, Kavitha Ramchandran
Provision of study materials or patients: Manali I. Patel, Rachel Hildebrand, Kaidi Moore, Sandhya Srinivas, Heather Wakelee, Kavitha Ramchandran
Collection and assembly of data: Michael F. Gensheimer, Divya Gupta, Manali I. Patel, Touran Fardeen, Rachel Hildebrand, Mary Khay Asuncion, Nina Alves, Brian Rogers, Jennifer Hansen, Joel Neal, Alice C. Fan, Kaidi Moore, Shann Ruiz, Connie Li, Ali Raza Khaki, Joanne Chien, Tiffany Brown, Alison Holmes Tisch, Sandhya Srinivas, Heather Wakelee, Howard Lee, Kavitha Ramchandran
Data analysis and interpretation: Michael F. Gensheimer, Divya Gupta, Manali I. Patel, Rachel Hildebrand, Mary Khay Asuncion, Nina Alves, Nigam H. Shah, Joel Neal, Alice C. Fan, Judy Pagtama, Millie Das, Sandhya Srinivas, Mohana Roy, Heather Wakelee, Nathaniel J. Myall, Jane Huang, Sumit Shah, Kavitha Ramchandran
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/op/authors/author-center.
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).
Michael F. Gensheimer
Employment: Roche/Genentech (I)
Stock and Other Ownership Interests: Roche/Genentech
Research Funding: Varian Medical Systems
Open Payments Link: https://openpaymentsdata.cms.gov/physician/431774
Nigam H. Shah
Leadership: Prealize, Atropos
Consulting or Advisory Role: Curai
Research Funding: Google (Inst)
Joel Neal
Honoraria: CME Matters, Clinical Care Options, Research to Practice, Medscape, Biomedical Learning Institute, Peerview, Prime Oncology, Projects in Knowledge, Rockpointe CME, MJH Life Sciences, Medical Educator Consortium, HMP Education
Consulting or Advisory Role: AstraZeneca, Genentech/Roche, Exelixis, Jounce Therapeutics, Takeda, Lilly, Calithera Biosciences, Amgen, Iovance Biotherapeutics, Blueprint Pharmaceuticals, Regeneron, Natera, Sanofi/Regeneron, D2G Oncology, Surface Oncology, Turning Point Therapeutics, Mirati Therapeutics, Gilead Sciences
Research Funding: Genentech/Roche (Inst), Merck (Inst), Novartis (Inst), Boehringer Ingelheim (Inst), Exelixis (Inst), Nektar (Inst), Takeda (Inst), Adaptimmune (Inst), GlaxoSmithKline (Inst), Janssen (Inst), AbbVie (Inst)
Patents, Royalties, Other Intellectual Property: UpToDate—Royalties
Alice C. Fan
Employment: Silverado Hospice, BeiGene
Stock and Other Ownership Interests: Molecular Decisions, Antelope Valley Care Center
Consulting or Advisory Role: Verily
Research Funding: Earli (Inst), Filtricine (Inst), MagARRAY (Inst), Calithera Biosciences (Inst)
Patents, Royalties, Other Intellectual Property: Stanford Patent has been licensed
Ali Raza Khaki
Honoraria: OncLive/MJH Life Sciences
Uncompensated Relationships: Seattle Genetics/Astellas
Joanne Chien
Honoraria: Janssen Oncology, Seattle Genetics, Coherus Biosciences
Consulting or Advisory Role: Coherus Biosciences, Seattle Genetics, Janssen Oncology
Travel, Accommodations, Expenses: Coherus Biosciences
Millie Das
Honoraria: Plexus
Consulting or Advisory Role: Jazz Pharmaceuticals, AstraZeneca, BeiGene, Sanofi
Research Funding: Novartis, Verily, Varian Medical Systems, AbbVie, United Therapeutics, Cellsight Technologies
Sandhya Srinivas
Consulting or Advisory Role: Eisai, Bayer, Bristol Myers Squibb, Merck, AstraZeneca, Seattle Genetics, Janssen Oncology, Novartis
Research Funding: Bristol Myers Squibb (Inst), Genentech (Inst), Merck (Inst), Exelixis (Inst), Eisai (Inst), Bayer (Inst), AstraZeneca (Inst), Seattle Genetics/Astellas (Inst)
Other Relationship: Pfizer
Mohana Roy
Speakers' Bureau: MJH Life Sciences
Research Funding: Varian Medical Systems (Inst)
Heather Wakelee
Consulting or Advisory Role: AstraZeneca, Mirati Therapeutics, Blueprint Medicines
Research Funding: Genentech/Roche (Inst), Celgene (Inst), AstraZeneca/MedImmune (Inst), Novartis (Inst), Clovis Oncology (Inst), Xcovery (Inst), Bristol Myers Squibb (Inst), ACEA Biosciences (Inst), Arrys Therapeutics (Inst), Merck (Inst), Seattle Genetics (Inst), Helsinn Therapeutics (Inst)
Uncompensated Relationships: Merck, Genentech/Roche
Nathaniel J. Myall
Honoraria: Patient Power
Jane Huang
Employment: Beigene, Prelude Therapeutics
Leadership: 858 Therapeutics, Protara Therapeutics, Prelude Therapeutics, BeiGene
Stock and Other Ownership Interests: Protara Therapeutics, BeiGene, 858 Therapeutics, Prelude Therapeutics
Consulting or Advisory Role: BeiGene
Sumit Shah
Honoraria: Janssen
Consulting or Advisory Role: Natera, Grand Rounds/Included Health
Research Funding: Genentech
Howard Lee
Employment: Silverado Hospice
Leadership: AV Supportive Care & Hospice
Stock and Other Ownership Interests: AV Supportive Care & Hospice
Consulting or Advisory Role: BeiGene
Patents, Royalties, Other Intellectual Property: Stanford patent licensed
Kavitha Ramchandran
Consulting or Advisory Role: Drishti, GroupWell, Varian Medical Systems
No other potential conflicts of interest were reported.